Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
USD 2,516.2 million absolute opportunity is expected by 2036
E.GijonM.KennedyP
Toxicol Pathol 16, 3545
However, many of these technologies remain preclinical or are early in development, and larger-scale, longer-term studies are required to more conclusively assess their long-term effectiveness, safety, and cost-efficiency before routine clinical use
Furthermore, formulation, dosage and safety aspects of microbial supplementation should be considered for efficient application of riboflavin-producing bacteria in clinical settings
US$ 29.07
US$ 29.14
US$ 25.00
US$ 25.45
US$ 24.58
US$ 22.59
